Oral Care Drives OTC Sales As Glaxo Buffs Its Consumer Health Shine
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
GlaxoSmithKline consumer health sales grow 3% at constant exchange rates during the second quarter driven by Sensodyne oral care and medicated skin care products. CEO Emma Walmsley dismisses rumors of divesting the business, saying firm continues to see “very good potential for growth and performance” of consumer health.